Management of Type 1 Diabetes

Authored by , Reviewed by Dr Hayley Willacy | Last edited | Meets Patient’s editorial guidelines

This article is for Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Type 1 Diabetes article more useful, or one of our other health articles.


Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.

Type 1 diabetes describes a condition in which the pancreas is no longer able to produce sufficient insulin due to the destruction of the pancreatic beta cells by an autoimmune process. It is a condition which occurs predominantly in younger people, from childhood to young adults, and is increasing in the population, particularly in the under-5 age group. See the separate Diabetes Mellitus article.

Type 1 diabetes accounts for over 90% of diabetes in young people aged under 25 years. 12-15% of young people aged under 15 years with diabetes have an affected first-degree relative. Children are three times more likely to develop diabetes if their father has diabetes than if their mother has diabetes[1].

The successful management of the person with diabetes depends on working in partnership with the person affected and all members of the team responsible for the various elements of their care. Before a management plan can be agreed, an initial assessment of the health and lifestyle of the patient must be undertaken with particular reference to[1]:

History

  • Diabetic history, both recent and historical.
  • Symptoms of potential complications - eg, deterioration in eyesight.
  • Other medical conditions.
  • Drug history, current medications.
  • Family history.
  • Occupation and social history - eg, level of exercise, type of diet, smoking history, use of alcohol and recreational drugs.
  • Prior knowledge of, attitudes to and concerns about the condition.

Examination

  • General examination.
  • Height/weight/BMI.
  • Examination of feet (eg, ulcers, loss of sensation).
  • Examination of eyes (eg, cataracts, diabetic retinopathy).
  • Blood pressure measurement.
  • Examination of peripheral pulses.

Investigations[2]

Consideration should be given to performing the following investigations, depending on age and previous history of the condition:

  • Urine albumin excretion: albumin:creatinine ratio (ACR).
  • Glycated haemoglobin (HbA1c).
  • U&Es, estimated glomerular filtration rate (eGFR).
  • TFTs.
  • Full lipid profile (including HDL and LDL cholesterol and triglycerides).
  • Consider measurement of C-peptide and/or diabetes-specific autoantibody titres if there is a doubt as to whether a person has type 1 or type 2 diabetes.
  • Serological testing for coeliac disease at diagnosis[3].

Referral

When type 1 diabetes has been diagnosed, initial referral to hospital is often required. Urgent referral is essential if the person is unwell or for pregnant women. See the separate Diabetes in Pregnancy article.

However, if the person is well and sufficient expertise, care and support are available then the initial care and management can be provided at home. The Scottish Intercollegiate Guidelines Network (SIGN) has recommended that a home-based programme for initial management and education of children with diabetes and their families is an appropriate alternative to a hospital-based programme[1].

Consider referring adults with type 1 diabetes, who have recurrent severe hypoglycaemia that has not responded to other treatments, to a centre that assesses people for islet and/or pancreas transplantation. Consider islet or pancreas transplantation for adults with type 1 diabetes with suboptimal diabetes control who have had a renal transplant and are currently on immunosuppressive therapy[2]

Lifestyle issues

See the separate Diabetes Education and Self-management Programmes article.

  • Discuss diet and give dietary advice taking into account other factors - eg, obesity, hypertension, renal impairment; offer referral to a dietician.
  • Advise that regular physical activity can reduce arterial risk in the medium to long term and, where appropriate, discuss adjustments to insulin regime or calorie intake during exercise.
  • Give advice and support on smoking cessation where appropriate.
  • Ask the patient to consider wearing a medical emergency identification bracelet or similar.
  • If appropriate, advise of the need to contact the DVLA to inform them of the diagnosis[4].
  • Advise the patient to carry insulin in their hand luggage if they are travelling.

Insulin therapy and blood glucose monitoring

Patients with type 1 diabetes require insulin therapy. See the separate Insulin Regimens article.

  • The National Institute for Health and Care Excellence (NICE) recommends offering multiple daily injection basal-bolus insulin regimens as the insulin injection regimen of choice for all adults with type 1 diabetes. Do not offer adults newly diagnosed with type 1 diabetes non‑basal-bolus insulin regimens (that is, twice‑daily mixed, basal only or bolus only).
  • Once stabilised, discuss patient preferences for twice-daily or multiple injection regimes.
  • Arrive at the regime in partnership with the patient, as patients arriving at informed shared decisions with their practitioner are more likely to be successfully controlled with the chosen regime.
  • Offer twice-daily insulin detemir as basil insulin therapy.
  • Alternatively, consider one of the following:
    • An insulin regimen that is already being used by the person if it is meeting their agreed treatment goals.
    • Once-daily insulin glargine (100 units/ml) if insulin detemir is not tolerated or the person has a strong preference for once‑daily basal injections.
    • Once-daily insulin degludec (100 units/ml) if there is a particular concern about nocturnal hypoglycaemia.
    • Once-daily ultra-long-acting insulin such as degludec (100 units/ml) for people who need help from a carer or healthcare professional to administer injections.
  • Multiple injection regimes using unmodified or 'soluble' insulin or rapid-acting insulin analogues, are suitable for well-motivated individuals with a good understanding of disease control, or those with active or erratic lifestyles.
  • Biosimilar insulins (a biological copy) are now available at a cost saving to the NHS. The decision to change to a biosimilar should be made jointly after discussion between patient and prescriber.
  • Acquisition cost should be taken into account.
  • Ensure that insulin is prescribed by brand name.
  • Patients should be given instruction in injection technique using a device best suited to each patient's requirements.
  • Advise routine self-monitoring of blood glucose levels for all people with type 1
    diabetes and recommend testing at least four times a day, including before each
    meal and before bed[2].
  • Advise adults with type 1 diabetes to aim for a fasting plasma glucose level of 5-7 mmol/L on waking, and a plasma glucose level of 4-7 mmol/L before meals at other times of the day[2].
  • Give advice on how to change the regime in case of illness. See the separate Diabetes and Intercurrent Illness article.
  • Consider a Dose Adjustment For Normal Eating (DAFNE) programme[5]. See the separate Diabetes Education and Self-management Programmes article.
  • Give advice on how to recognise a hypoglycaemic episode and what action to take.
  • Advise patients to carry a source of glucose in case of hypoglycaemic episodes.
  • Consider training a partner/parent in the administration of glucagon.
  • Patients should be made aware of contact numbers for advice and it may be helpful to provide written information and/or details of how to access further information if required.

Review assessment[2]

All people with diabetes should be reviewed at least annually and more frequently if there are any factors which may cause concern to the patient or their doctor. The aim of regular review should be to assess and decrease the risk of known complications of diabetes, such as peripheral arterial disease, nephropathy and retinopathy. A review appointment may involve many healthcare workers, such as the dietician, optometrist, podiatrist or other appropriately trained members of staff. Use of a review protocol will ensure that all areas are covered. A review appointment should include:

  • Glycaemic control:
    • Reinforce the need for lifestyle measures. See the separate Diabetes Diet and Exercise article.
    • HbA1c: agree an individualised HbA1c target with each adult with type 1 diabetes, taking into account factors such as the person's daily activities, aspirations, likelihood of complications, comorbidities, occupation and history of hypoglycaemia.
  • BMI.
  • Full lipid profile.
  • Urinary albumin excretion: ACR.
  • Renal function: eGFR.
  • Measure blood thyroid-stimulating hormone (TSH) levels in adults with type 1 diabetes at annual review.
  • Blood pressure measurement: intervention levels for recommending blood pressure management should be 135/85 mm Hg unless the adult with type 1 diabetes has albuminuria or two or more features of metabolic syndrome, in which case it should be 130/80 mm Hg - maintain below 130/80 mm Hg.
  • Examination of eyes for signs of retinopathy and cataracts.
  • Examination of feet for ulceration/sensation/peripheral pulses.
  • Examination of injection sites.
  • If the patient is male, ask about impotence.
  • Females will need pre-conception advice when appropriate.

Children and young adults

Offer children and young people with type 1 diabetes monitoring for[6]:

  • Thyroid disease at diagnosis and then annually until transfer to adult services.
  • Diabetic retinopathy annually from age 12 years.
  • Microalbuminuria (ACR 3-30 mg/mmol) to detect diabetic kidney disease, annually from age 12 years.
  • Hypertension annually from age 12 years.
  • Without insulin replacement, people with type 1 diabetes are likely to die within days or weeks.
  • With insulin replacement, people with type 1 diabetes can participate normally in the usual activities of daily life but are at risk of complications.
  • The risk of disability associated with complications is greatly reduced by adherence to a healthy lifestyle, good glucose, lipid and blood pressure control and early detection and management of any complications.

Are you protected against flu?

See if you are eligible for a free NHS flu jab today.

Check now

Further reading and references

  1. Management of diabetes; Scottish Intercollegiate Guidelines Network - SIGN (March 2010 - updated November 2017)

  2. Type 1 diabetes in adults: diagnosis and management; NICE Guidelines (August 2015 - last updated July 2021)

  3. Coeliac disease: recognition, assessment and management; NICE Guidance (September 2015)

  4. Assessing fitness to drive: guide for medical professionals; Driver and Vehicle Licensing Agency

  5. Dose Adjustment For Normal Eating; (DAFNE), 2021

  6. Diabetes (type 1 and type 2) in children and young people: diagnosis and management; NICE Guidelines (Aug 2015 - updated Dec 2020)

  7. Diabetes - Type 1; NICE CKS, November 2020 (UK access only)

I am just over a month of diabetes diagnosis. I was put on metformin twice a day. I just went to new primary care and she wants to add Ozempic injections once a week. She says it has also helped with...

vickie15389
Health Tools

Feeling unwell?

Assess your symptoms online with our free symptom checker.

Start symptom checker
newnav-downnewnav-up